In Vitro Diagnostic Kit

About NuView Life Sciences

NuView Life Sciences is pioneering a targeted copper theranostics (TCT) platform centered on its proprietary NV-VPAC1 ligand, which binds to VPAC1 receptors overexpressed on a wide range of cancers. The company is developing a pipeline of in vitro diagnostics, PET imaging agents, and radiotherapeutics for cancers including prostate, bladder, breast, brain, and pancreatic. Its approach aims to offer precise tumor localization and targeted treatment delivery, potentially improving patient outcomes and expanding access to radiopharmaceuticals. NuView is a private, clinical-stage company with a robust intellectual property portfolio and multiple programs advancing toward clinical development.

Therapeutic Areas